Drug and Therapeutics Bulletin 2004;42:65-67; doi:10.1136/dtb.2004.42965
Copyright © 2004 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

{blacktriangledown}Ezetimibe - a new cholesterol-lowering drug

Relevant BNF section: 2.12

Use of statin therapy is a key first-line approach in preventing coronary heart disease events and stroke in people at increased risk of developing such complications. {blacktriangledown}Ezetimibe (Ezetrol - MSD-Schering-Plough), the first licensed azetidinone drug, is being promoted as an adjunct to statin therapy to achieve greater reductions in blood cholesterol concentrations than occur with a statin alone. Here we review ezetimibe and consider its place in clinical practice.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2004 BMJ Publishing Group Ltd.